Assessing proarrhythmic potential of drugs when optimal studies are infeasible

Edwin P. Rock, John Finkle, Howard J. Fingert, Brian P. Booth, Christine E. Garnett, Stephen Grant, Robert L. Justice, Richard Kovacs, Peter R. Kowey, Ignacio Rodriguez, Wendy R. Sanhai, Colette Strnadova, Shari L. Targum, Yi Tsong, Kathleen Uhl, Norman Stockbridge

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

Assessing the potential for a new drug to cause life-threatening arrhythmias is now an integral component of premarketing safety assessment. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use Guideline (ICH) E14 recommends the "Thorough QT Study" (TQT) to assess clinical QT risk. Such a study calls for careful evaluation of drug effects on the electrocardiographic QT interval at multiples of therapeutic exposure and with a positive control to confirm assay sensitivity. Yet for some drugs and diseases, elements of the TQT Study may be impractical or unethical. In these instances, alternative approaches to QT risk assessment must be considered. This article presents points to consider for evaluation of QT risk when alternative approaches are needed.

Original languageEnglish
JournalAmerican Heart Journal
Volume157
Issue number5
DOIs
StatePublished - May 2009

Fingerprint

Pharmaceutical Preparations
Drug Evaluation
Cardiac Arrhythmias
Guidelines
Safety
Therapeutics

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Rock, E. P., Finkle, J., Fingert, H. J., Booth, B. P., Garnett, C. E., Grant, S., ... Stockbridge, N. (2009). Assessing proarrhythmic potential of drugs when optimal studies are infeasible. American Heart Journal, 157(5). https://doi.org/10.1016/j.ahj.2009.02.020

Assessing proarrhythmic potential of drugs when optimal studies are infeasible. / Rock, Edwin P.; Finkle, John; Fingert, Howard J.; Booth, Brian P.; Garnett, Christine E.; Grant, Stephen; Justice, Robert L.; Kovacs, Richard; Kowey, Peter R.; Rodriguez, Ignacio; Sanhai, Wendy R.; Strnadova, Colette; Targum, Shari L.; Tsong, Yi; Uhl, Kathleen; Stockbridge, Norman.

In: American Heart Journal, Vol. 157, No. 5, 05.2009.

Research output: Contribution to journalArticle

Rock, EP, Finkle, J, Fingert, HJ, Booth, BP, Garnett, CE, Grant, S, Justice, RL, Kovacs, R, Kowey, PR, Rodriguez, I, Sanhai, WR, Strnadova, C, Targum, SL, Tsong, Y, Uhl, K & Stockbridge, N 2009, 'Assessing proarrhythmic potential of drugs when optimal studies are infeasible', American Heart Journal, vol. 157, no. 5. https://doi.org/10.1016/j.ahj.2009.02.020
Rock, Edwin P. ; Finkle, John ; Fingert, Howard J. ; Booth, Brian P. ; Garnett, Christine E. ; Grant, Stephen ; Justice, Robert L. ; Kovacs, Richard ; Kowey, Peter R. ; Rodriguez, Ignacio ; Sanhai, Wendy R. ; Strnadova, Colette ; Targum, Shari L. ; Tsong, Yi ; Uhl, Kathleen ; Stockbridge, Norman. / Assessing proarrhythmic potential of drugs when optimal studies are infeasible. In: American Heart Journal. 2009 ; Vol. 157, No. 5.
@article{2833cf61fa544113a875e58f7ff8de3d,
title = "Assessing proarrhythmic potential of drugs when optimal studies are infeasible",
abstract = "Assessing the potential for a new drug to cause life-threatening arrhythmias is now an integral component of premarketing safety assessment. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use Guideline (ICH) E14 recommends the {"}Thorough QT Study{"} (TQT) to assess clinical QT risk. Such a study calls for careful evaluation of drug effects on the electrocardiographic QT interval at multiples of therapeutic exposure and with a positive control to confirm assay sensitivity. Yet for some drugs and diseases, elements of the TQT Study may be impractical or unethical. In these instances, alternative approaches to QT risk assessment must be considered. This article presents points to consider for evaluation of QT risk when alternative approaches are needed.",
author = "Rock, {Edwin P.} and John Finkle and Fingert, {Howard J.} and Booth, {Brian P.} and Garnett, {Christine E.} and Stephen Grant and Justice, {Robert L.} and Richard Kovacs and Kowey, {Peter R.} and Ignacio Rodriguez and Sanhai, {Wendy R.} and Colette Strnadova and Targum, {Shari L.} and Yi Tsong and Kathleen Uhl and Norman Stockbridge",
year = "2009",
month = "5",
doi = "10.1016/j.ahj.2009.02.020",
language = "English",
volume = "157",
journal = "American Heart Journal",
issn = "0002-8703",
publisher = "Mosby Inc.",
number = "5",

}

TY - JOUR

T1 - Assessing proarrhythmic potential of drugs when optimal studies are infeasible

AU - Rock, Edwin P.

AU - Finkle, John

AU - Fingert, Howard J.

AU - Booth, Brian P.

AU - Garnett, Christine E.

AU - Grant, Stephen

AU - Justice, Robert L.

AU - Kovacs, Richard

AU - Kowey, Peter R.

AU - Rodriguez, Ignacio

AU - Sanhai, Wendy R.

AU - Strnadova, Colette

AU - Targum, Shari L.

AU - Tsong, Yi

AU - Uhl, Kathleen

AU - Stockbridge, Norman

PY - 2009/5

Y1 - 2009/5

N2 - Assessing the potential for a new drug to cause life-threatening arrhythmias is now an integral component of premarketing safety assessment. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use Guideline (ICH) E14 recommends the "Thorough QT Study" (TQT) to assess clinical QT risk. Such a study calls for careful evaluation of drug effects on the electrocardiographic QT interval at multiples of therapeutic exposure and with a positive control to confirm assay sensitivity. Yet for some drugs and diseases, elements of the TQT Study may be impractical or unethical. In these instances, alternative approaches to QT risk assessment must be considered. This article presents points to consider for evaluation of QT risk when alternative approaches are needed.

AB - Assessing the potential for a new drug to cause life-threatening arrhythmias is now an integral component of premarketing safety assessment. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use Guideline (ICH) E14 recommends the "Thorough QT Study" (TQT) to assess clinical QT risk. Such a study calls for careful evaluation of drug effects on the electrocardiographic QT interval at multiples of therapeutic exposure and with a positive control to confirm assay sensitivity. Yet for some drugs and diseases, elements of the TQT Study may be impractical or unethical. In these instances, alternative approaches to QT risk assessment must be considered. This article presents points to consider for evaluation of QT risk when alternative approaches are needed.

UR - http://www.scopus.com/inward/record.url?scp=64349093768&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=64349093768&partnerID=8YFLogxK

U2 - 10.1016/j.ahj.2009.02.020

DO - 10.1016/j.ahj.2009.02.020

M3 - Article

VL - 157

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

IS - 5

ER -